Sylvie Gregoire Purchases 10,807 Shares of CervoMed (NASDAQ:CRVO) Stock

CervoMed Inc. (NASDAQ:CRVO) Director Sylvie Gregoire purchased 10,807 shares of the business’s stock in a transaction on Monday, November 17th. The stock was purchased at an average cost of $8.46 per share, for a total transaction of $91,427.22. Following the acquisition, the director owned 12,500 shares in the company, valued at approximately $105,750. The trade was a 638.33% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Sylvie Gregoire also recently made the following trade(s):

• On Monday, November 17th, Sylvie Gregoire acquired 10,793 shares of CervoMed stock. The stock was acquired at an average price of $8.46 per share, with a total value of $91,308.78.
• On Friday, November 14th, Sylvie Gregoire purchased 1,693 shares of CervoMed stock. The stock was acquired at an average cost of $7.55 per share, with a total value of $12,782.15.
• On Friday, November 14th, Sylvie Gregoire bought 1,707 shares of CervoMed stock. The shares were bought at an average cost of $7.57 per share, for a total transaction of $12,921.99.
• On Thursday, November 13th, Sylvie Gregoire bought 4,447 shares of CervoMed stock. The shares were purchased at an average price of $7.51 per share, for a total transaction of $33,396.97.
• On Wednesday, November 12th, Sylvie Gregoire bought 5,553 shares of CervoMed stock. The shares were acquired at an average price of $7.35 per share, for a total transaction of $40,814.55.

CervoMed Stock Up 5.7%

CervoMed stock opened at $8.78 on Wednesday. The stock’s 50 day moving average is $7.81 and its 200 day moving average is $8.11. The company has a market capitalization of $81.20 million, a P/E ratio of -3.36 and a beta of -0.89. CervoMed Inc. has a twelve month low of $1.80 and a twelve month high of $16.94.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $1.43 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. As a group, equities analysts expect that CervoMed Inc. will post -1.88 EPS for the current year.

Analyst Ratings Changes

CRVO has been the subject of several recent research reports. Chardan Capital restated a “buy” rating and set a $15.00 target price on shares of CervoMed in a research report on Monday, August 11th. Canaccord Genuity Group boosted their price target on CervoMed from $21.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. D. Boral Capital reaffirmed a “buy” rating and set a $31.00 price objective on shares of CervoMed in a research report on Tuesday, November 11th. HC Wainwright upgraded shares of CervoMed from a “neutral” rating to a “buy” rating and raised their target price for the stock from $11.00 to $25.00 in a research note on Wednesday, November 5th. Finally, Zacks Research lowered shares of CervoMed from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, CervoMed has an average rating of “Moderate Buy” and an average price target of $21.86.

Institutional Trading of CervoMed

Institutional investors have recently bought and sold shares of the stock. AWM Investment Company Inc. purchased a new position in shares of CervoMed during the 1st quarter worth about $7,898,000. Vanguard Group Inc. lifted its position in shares of CervoMed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after purchasing an additional 3,445 shares during the period. Jane Street Group LLC purchased a new stake in shares of CervoMed during the 2nd quarter worth $414,000. Nuveen LLC purchased a new position in shares of CervoMed in the 1st quarter worth approximately $312,000. Finally, Citadel Advisors LLC acquired a new stake in CervoMed in the third quarter worth about $247,000. 25.15% of the stock is currently owned by institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.